The Experts below are selected from a list of 47004 Experts worldwide ranked by ideXlab platform
Xiaoyuan Chen - One of the best experts on this subject based on the ideXlab platform.
-
gastrin releasing peptide receptor pet imaging with 68ga nota aca bbn 7 14 and 68ga nota irdye800cw bbn for evaluation of glioma patients a prospective pilot study
The Journal of Nuclear Medicine, 2018Co-Authors: Jing-jing Zhang, Zhaohui Zhu, Jie Zang, Hao Wang, Guozhu Hou, Lixin Lang, Gang Niu, Xiaoyuan ChenAbstract:81 Objectives: This study was designed to assess PET imaging using gastrin-releasing peptide receptor (GRPR) targeting tracers 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-NOTA-IRDye800CW-BBN, in the detection and preoperative evaluation of glioma. Methods: With institutional review board approval and written informed consent, 46 patients with suspected brain glioma as evaluated by contrast-enhanced MRI were recruited. Among the 46 patients, 34 patients received PET/CT and the other 12 patients received simultaneous PET/MR. A single dose of 74-148 MBq 68Ga-NOTA-Aca-BBN(7-14) or 68Ga-NOTA-IRDye800CW-BBN was injected intravenously. PET/CT and PET/MR scanning was performed at 30 min after the administration of 68Ga-NOTA-Aca-BBN(7-14), or at 30 min and 60 min after the administration of 68Ga-IRDye800CW-BBN. 3 patients accepted PET scanning with both 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-IRDye800CW-BBN within one week for comparative analysis of the two tracers. Radioactivity concentrations and the mean and maximum standardized uptake values (SUVs) in these volumes of interest were obtained using the workstation software. For the patients who underwent PET/CT, PET images were co-registered to MR images with automatic image registration and manual positioning was performed. All the 46 patients underwent surgical removal of their tumor within 1 week after brain PET imaging. Among them, 24 patients also accepted GRPR targeting IRDye800CW-BBN NIRF intraoperatively. A final diagnosis was made based on the histopathologic examination with immunohistochemical staining of tumor samples against GRPR. Results: Among the 46 patients, 80.4% (37/46) patients in this study were found positive tracer accumulation in brain lesions with excellent contrast from surrounding normal brain tissue on PET. Similar biodistributions between 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-IRDye800CW-BBN PET were observed, while with additional uptake of brain blood pool on 68Ga-IRDye800CW-BBN PET at 30 and 60 min after tracer administration and lower uptake in normal brain tissues with the mean SUVs of 0.07 ± 0.03 (n=10) compared with 0.09 ± 0.04 (n=40) on 68Ga-NOTA-Aca-BBN(7-14) PET (P
-
18f labeled bombesin analogs for targeting grp receptor expressing prostate cancer
The Journal of Nuclear Medicine, 2006Co-Authors: Xianzhong Zhang, Weibo Cai, Feng Cao, E Schreibmann, Lei Xing, Xiaoyuan ChenAbstract:The gastrin-releasing peptide receptor (GRPR) is found to be overexpressed in a variety of human tumors. The aim of this study was to develop 18F-labeled bombesin analogs for PET of GRPR expression in prostate cancer xenograft models. Methods: [Lys3]Bombesin ([Lys3]BBN) and aminocaproic acid-bombesin(7–14) (Aca-BBN(7–14)) were labeled with 18F by coupling the Lys3 amino group and Aca amino group, respectively, with N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) under slightly basic condition (pH 8.5). Receptor-binding affinity of FB-[Lys3]BBN and FB-Aca-BBN(7–14) was tested in PC-3 human prostate carcinoma cells. Internalization and efflux of both radiotracers were also evaluated. Tumor-targeting efficacy and in vivo kinetics of both radiotracers were examined in male athymic nude mice bearing subcutaneous PC-3 tumors by means of biodistribution and dynamic microPET imaging studies. 18F-FB-[Lys3]BBN was also tested for orthotopic PC-3 tumor delineation. Metabolic stability of 18F-FB-[Lys3]BBN was determined in mouse blood, urine, liver, kidney, and tumor homogenates at 1 h after injection. Results: The typical decay-corrected radiochemical yield was about 30%–40% for both tracers, with a total reaction time of 150 ± 20 min starting from 18F−. 18F-FB-[Lys3]BBN had moderate stability in the blood and PC-3 tumor, whereas it was degraded rapidly in the liver, kidneys, and urine. Both radiotracers exhibited rapid blood clearance. 18F-FB-[Lys3]BBN had predominant renal excretion. 18F-FB-Aca-BBN(7–14) exhibited both hepatobiliary and renal clearance. Dynamic microPET imaging studies revealed that the PC-3 tumor uptake of 18F-FB-[Lys3]BBN in PC-3 tumor was much higher than that of 18F-FB-Aca-BBN(7–14) at all time points examined (P
Zhaohui Zhu - One of the best experts on this subject based on the ideXlab platform.
-
gastrin releasing peptide receptor pet imaging with 68ga nota aca bbn 7 14 and 68ga nota irdye800cw bbn for evaluation of glioma patients a prospective pilot study
The Journal of Nuclear Medicine, 2018Co-Authors: Jing-jing Zhang, Zhaohui Zhu, Jie Zang, Hao Wang, Guozhu Hou, Lixin Lang, Gang Niu, Xiaoyuan ChenAbstract:81 Objectives: This study was designed to assess PET imaging using gastrin-releasing peptide receptor (GRPR) targeting tracers 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-NOTA-IRDye800CW-BBN, in the detection and preoperative evaluation of glioma. Methods: With institutional review board approval and written informed consent, 46 patients with suspected brain glioma as evaluated by contrast-enhanced MRI were recruited. Among the 46 patients, 34 patients received PET/CT and the other 12 patients received simultaneous PET/MR. A single dose of 74-148 MBq 68Ga-NOTA-Aca-BBN(7-14) or 68Ga-NOTA-IRDye800CW-BBN was injected intravenously. PET/CT and PET/MR scanning was performed at 30 min after the administration of 68Ga-NOTA-Aca-BBN(7-14), or at 30 min and 60 min after the administration of 68Ga-IRDye800CW-BBN. 3 patients accepted PET scanning with both 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-IRDye800CW-BBN within one week for comparative analysis of the two tracers. Radioactivity concentrations and the mean and maximum standardized uptake values (SUVs) in these volumes of interest were obtained using the workstation software. For the patients who underwent PET/CT, PET images were co-registered to MR images with automatic image registration and manual positioning was performed. All the 46 patients underwent surgical removal of their tumor within 1 week after brain PET imaging. Among them, 24 patients also accepted GRPR targeting IRDye800CW-BBN NIRF intraoperatively. A final diagnosis was made based on the histopathologic examination with immunohistochemical staining of tumor samples against GRPR. Results: Among the 46 patients, 80.4% (37/46) patients in this study were found positive tracer accumulation in brain lesions with excellent contrast from surrounding normal brain tissue on PET. Similar biodistributions between 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-IRDye800CW-BBN PET were observed, while with additional uptake of brain blood pool on 68Ga-IRDye800CW-BBN PET at 30 and 60 min after tracer administration and lower uptake in normal brain tissues with the mean SUVs of 0.07 ± 0.03 (n=10) compared with 0.09 ± 0.04 (n=40) on 68Ga-NOTA-Aca-BBN(7-14) PET (P
-
Diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial
2017Co-Authors: Zhaohui ZhuAbstract:Background: Gastrin-releasing peptide receptor is particularly expressed in gliomas, while the peptide bombesin [BBN(7-14)] has the complete C-terminal structure of human gastrin-releasing peptide. Glioma-specific imaging agents can therefore be constructed from BBN, for example 68Ga-NOTA-Aca-BBN(7-14). For consideration of the clinical translation of 68Ga-NOTA-Aca-BBN(7-14), an open-label dynamic whole-body positron emission tomography/computed tomography (PET/CT) study was designed to investigate the diagnostic effectiveness and safety of 68Ga-NOTA-Aca-BBN(7-14) in patients with brain gliomas.Methods/Design: This is an open-label single-arm clinical trial that will be conducted at Peking Union Medical College Hospital in Beijing, China. Thirty patients in suspicion of brain gliomas scheduled for surgical treatment will be recruited and subjected to PET/CT via intravenous injection of 68Ga-NOTA-Aca-BBN(7-14). The primary outcome measure will be the standardized uptake value of 68Ga-NOTA-Aca-BBN(7-14) in brain glioma at 30 minutes after injection. Secondary outcomes include the diagnostic accuracy rate of 68Ga-NOTA-Aca-BBN(7-14) PET/CT, and adverse events after injection.Discussion: Diagnostic performance and safety assessment of 68Ga-NOTA-Aca-BBN(7-14) in brain gliomas will provide new insights into the specific PET/CT diagnosis of brain gliomas.Trial registration: ClinicalTrials.gov identifier: NCT02520882, registered on 2 August 2015.doi: 10.4103/2542-3932.198959How to cite this article: Zang J, Wang H, Zhang JJ, Zhu ZH (2017) Diagnostic performance of 68Ga-NOTA-Aca-BBN (7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial. Asia Pac J Clin Trials Nerv Syst Dis 2(1):23-29.
-
Diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial
Wolters Kluwer Medknow Publications, 2017Co-Authors: Jie Zang, Hao Wang, Jing-jing Zhang, Zhaohui ZhuAbstract:Background: Gastrin-releasing peptide receptor is particularly expressed in gliomas, while the peptide bombesin [BBN(7-14)] has the complete C-terminal structure of human gastrin-releasing peptide. Glioma-specific imaging agents can therefore be constructed from BBN, for example 68Ga-NOTA-Aca-BBN(7-14). For consideration of the clinical translation of 68Ga-NOTA-Aca-BBN(7-14), an open-label dynamic whole-body positron emission tomography/computed tomography (PET/CT) study was designed to investigate the diagnostic effectiveness and safety of 68Ga-NOTA-Aca-BBN(7-14) in patients with brain gliomas. Methods/Design: This is an open-label single-arm clinical trial that will be conducted at Peking Union Medical College Hospital in Beijing, China. Thirty patients in suspicion of brain gliomas scheduled for surgical treatment will be recruited and subjected to PET/CT via intravenous injection of 68Ga-NOTA-Aca-BBN(7-14). The primary outcome measure will be the standardized uptake value of 68Ga-NOTA-Aca-BBN(7-14) in brain glioma at 30 minutes after injection. Secondary outcomes include the diagnostic accuracy rate of 68Ga-NOTA-Aca-BBN(7-14) PET/CT, and adverse events after injection. Discussion: Diagnostic performance and safety assessment of 68Ga-NOTA-Aca-BBN(7-14) in brain gliomas will provide new insights into the specific PET/CT diagnosis of brain gliomas. Trial registration: ClinicalTrials.gov identifier: NCT02520882, registered on 2 August 2015. Ethics: This study protocol has been approved by the Ethics Committee of Peking Union Medical College Hospital in China (approval No. S-714), and will be performed in accordance with the Declaration of Helsinki, formulated by the World Medical Association. Informed consent: An informed consent will be obtained from each patient or his/her guardian prior to participation in the study
Youngsoo Kim - One of the best experts on this subject based on the ideXlab platform.
-
deacylation activity of cephalosporin acylase to cephalosporin c is improved by changing the side chain conformations of active site residues
Biochemical and Biophysical Research Communications, 2003Co-Authors: Myungsook Kim, Jongchul Yoon, Kyungwha Chung, Yong Chul Shin, Dongsoon Lee, Youngsoo KimAbstract:Abstract Semisynthetic cephalosporins are primarily synthesized from 7-aminocephalosporanic acid (7-ACA), mainly by environmentally toxic chemical deacylation of cephalosporin C (CPC). Thus, the enzymatic conversion of CPC to 7-ACA by cephalosporin acylase (CA) would be very interesting. However, CAs use glutaryl-7-ACA (GL-7-ACA) as a primary substrate and the enzymes have low turnover rates for CPC. The active-site residues of a CA were mutagenized to various residues to increase the deacylation activity of CPC, based on the active-site conformation of the CA structure. The aim was to generate sterically favored conformation of the active-site to accommodate the d -α-aminoadipyl moiety of CPC, the side-chain moiety that corresponds to the glutaryl moiety of GL-7-ACA. A triple mutant of the CA, Q50βM/Y149αK/F177βG, showed the greatest improvement of deacylation activity to CPC up to 790% of the wild-type. Our current study is an efficient method for improving the deacylation activity to CPC by employing the structure-based repetitive saturation mutagenesis.
-
active site residues of cephalosporin acylase are critical not only for enzymatic catalysis but also for post translational modification
Journal of Biological Chemistry, 2001Co-Authors: Sanggu Kim, Youngsoo KimAbstract:Abstract Cephalosporin acylase (CA) is a recently identified N-terminal hydrolase. It is also a commercially important enzyme in producing 7-aminocephalosporanic acid (7-ACA), a backbone chemical in synthesizing semi-synthetic cephalosporin antibiotics. CA is translated as an inactive single chain precursor, being post-translationally modified into an active enzyme. The post-translational modification takes place in two steps. The first intramolecular autocatalytic proteolysis takes place at one end of the spacer peptide by a nucleophilic Ser or Thr, which in turn becomes a new N-terminal Ser or Thr. The second intermolecular modification cleaves off the other end of the spacer peptide by another CA. Two binary structures in complex with glutaryl-7-ACA (the most favored substrate of CAs) and glutarate (side chain of glutaryl-7-ACA) were determined, and they revealed the detailed interactions of glutaryl-7-ACA with the active site residues (Y. Kim and W. G. J. Hol (2001) Chem. Biol., in press). In this report: 1) we have mutated key active site residues into nonfunctional amino acids, and their roles in catalysis were further analyzed; 2) we performed mutagenesis studies indicating that secondary intermolecular modification is carried out in the same active site where deacylation reaction of CA occurs; and 3) the cleavage site of secondary intermolecular modification by another CA was identified in the spacer peptide using mutational analysis. Finally, a schematic model for intermolecular cleavage of CA is proposed.
-
structure of cephalosporin acylase in complex with glutaryl 7 aminocephalosporanic acid and glutarate insight into the basis of its substrate specificity
Chemistry & Biology, 2001Co-Authors: Youngsoo Kim, Wim G J HolAbstract:Abstract Background: Semisynthetic cephalosporins are primarily synthesized from 7-aminocephalosporanic acid (7-ACA), which is obtained by environmentally toxic chemical deacylation of cephalosporin C (CPC). Thus, the enzymatic conversion of CPC to 7-ACA by cephalosporin acylase (CA) would be of great interest. However, CAs use glutaryl-7-ACA (GL-7-ACA) as a primary substrate and the enzyme has low turnover rates for CPC. Results: The binary complex structures of CA with GL-7-ACA and glutarate (the side-chain of GL-7-ACA) show extensive interactions between the glutaryl moiety of GL-7-ACA and the seven residues that form the side-chain pocket. These interactions explain why the D-α-aminoadipyl side-chain of CPC yields a poorer substrate than GL-7-ACA. Conclusions: This understanding of the nature of substrate specificity may be useful in the design of an enzyme with an improved performance for the conversion of CPC to 7-ACA. Additionally, the catalytic mechanism of the deacylation reaction was revealed by the ligand bound structures.
Jing-jing Zhang - One of the best experts on this subject based on the ideXlab platform.
-
gastrin releasing peptide receptor pet imaging with 68ga nota aca bbn 7 14 and 68ga nota irdye800cw bbn for evaluation of glioma patients a prospective pilot study
The Journal of Nuclear Medicine, 2018Co-Authors: Jing-jing Zhang, Zhaohui Zhu, Jie Zang, Hao Wang, Guozhu Hou, Lixin Lang, Gang Niu, Xiaoyuan ChenAbstract:81 Objectives: This study was designed to assess PET imaging using gastrin-releasing peptide receptor (GRPR) targeting tracers 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-NOTA-IRDye800CW-BBN, in the detection and preoperative evaluation of glioma. Methods: With institutional review board approval and written informed consent, 46 patients with suspected brain glioma as evaluated by contrast-enhanced MRI were recruited. Among the 46 patients, 34 patients received PET/CT and the other 12 patients received simultaneous PET/MR. A single dose of 74-148 MBq 68Ga-NOTA-Aca-BBN(7-14) or 68Ga-NOTA-IRDye800CW-BBN was injected intravenously. PET/CT and PET/MR scanning was performed at 30 min after the administration of 68Ga-NOTA-Aca-BBN(7-14), or at 30 min and 60 min after the administration of 68Ga-IRDye800CW-BBN. 3 patients accepted PET scanning with both 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-IRDye800CW-BBN within one week for comparative analysis of the two tracers. Radioactivity concentrations and the mean and maximum standardized uptake values (SUVs) in these volumes of interest were obtained using the workstation software. For the patients who underwent PET/CT, PET images were co-registered to MR images with automatic image registration and manual positioning was performed. All the 46 patients underwent surgical removal of their tumor within 1 week after brain PET imaging. Among them, 24 patients also accepted GRPR targeting IRDye800CW-BBN NIRF intraoperatively. A final diagnosis was made based on the histopathologic examination with immunohistochemical staining of tumor samples against GRPR. Results: Among the 46 patients, 80.4% (37/46) patients in this study were found positive tracer accumulation in brain lesions with excellent contrast from surrounding normal brain tissue on PET. Similar biodistributions between 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-IRDye800CW-BBN PET were observed, while with additional uptake of brain blood pool on 68Ga-IRDye800CW-BBN PET at 30 and 60 min after tracer administration and lower uptake in normal brain tissues with the mean SUVs of 0.07 ± 0.03 (n=10) compared with 0.09 ± 0.04 (n=40) on 68Ga-NOTA-Aca-BBN(7-14) PET (P
-
Diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial
Wolters Kluwer Medknow Publications, 2017Co-Authors: Jie Zang, Hao Wang, Jing-jing Zhang, Zhaohui ZhuAbstract:Background: Gastrin-releasing peptide receptor is particularly expressed in gliomas, while the peptide bombesin [BBN(7-14)] has the complete C-terminal structure of human gastrin-releasing peptide. Glioma-specific imaging agents can therefore be constructed from BBN, for example 68Ga-NOTA-Aca-BBN(7-14). For consideration of the clinical translation of 68Ga-NOTA-Aca-BBN(7-14), an open-label dynamic whole-body positron emission tomography/computed tomography (PET/CT) study was designed to investigate the diagnostic effectiveness and safety of 68Ga-NOTA-Aca-BBN(7-14) in patients with brain gliomas. Methods/Design: This is an open-label single-arm clinical trial that will be conducted at Peking Union Medical College Hospital in Beijing, China. Thirty patients in suspicion of brain gliomas scheduled for surgical treatment will be recruited and subjected to PET/CT via intravenous injection of 68Ga-NOTA-Aca-BBN(7-14). The primary outcome measure will be the standardized uptake value of 68Ga-NOTA-Aca-BBN(7-14) in brain glioma at 30 minutes after injection. Secondary outcomes include the diagnostic accuracy rate of 68Ga-NOTA-Aca-BBN(7-14) PET/CT, and adverse events after injection. Discussion: Diagnostic performance and safety assessment of 68Ga-NOTA-Aca-BBN(7-14) in brain gliomas will provide new insights into the specific PET/CT diagnosis of brain gliomas. Trial registration: ClinicalTrials.gov identifier: NCT02520882, registered on 2 August 2015. Ethics: This study protocol has been approved by the Ethics Committee of Peking Union Medical College Hospital in China (approval No. S-714), and will be performed in accordance with the Declaration of Helsinki, formulated by the World Medical Association. Informed consent: An informed consent will be obtained from each patient or his/her guardian prior to participation in the study
Jie Zang - One of the best experts on this subject based on the ideXlab platform.
-
gastrin releasing peptide receptor pet imaging with 68ga nota aca bbn 7 14 and 68ga nota irdye800cw bbn for evaluation of glioma patients a prospective pilot study
The Journal of Nuclear Medicine, 2018Co-Authors: Jing-jing Zhang, Zhaohui Zhu, Jie Zang, Hao Wang, Guozhu Hou, Lixin Lang, Gang Niu, Xiaoyuan ChenAbstract:81 Objectives: This study was designed to assess PET imaging using gastrin-releasing peptide receptor (GRPR) targeting tracers 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-NOTA-IRDye800CW-BBN, in the detection and preoperative evaluation of glioma. Methods: With institutional review board approval and written informed consent, 46 patients with suspected brain glioma as evaluated by contrast-enhanced MRI were recruited. Among the 46 patients, 34 patients received PET/CT and the other 12 patients received simultaneous PET/MR. A single dose of 74-148 MBq 68Ga-NOTA-Aca-BBN(7-14) or 68Ga-NOTA-IRDye800CW-BBN was injected intravenously. PET/CT and PET/MR scanning was performed at 30 min after the administration of 68Ga-NOTA-Aca-BBN(7-14), or at 30 min and 60 min after the administration of 68Ga-IRDye800CW-BBN. 3 patients accepted PET scanning with both 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-IRDye800CW-BBN within one week for comparative analysis of the two tracers. Radioactivity concentrations and the mean and maximum standardized uptake values (SUVs) in these volumes of interest were obtained using the workstation software. For the patients who underwent PET/CT, PET images were co-registered to MR images with automatic image registration and manual positioning was performed. All the 46 patients underwent surgical removal of their tumor within 1 week after brain PET imaging. Among them, 24 patients also accepted GRPR targeting IRDye800CW-BBN NIRF intraoperatively. A final diagnosis was made based on the histopathologic examination with immunohistochemical staining of tumor samples against GRPR. Results: Among the 46 patients, 80.4% (37/46) patients in this study were found positive tracer accumulation in brain lesions with excellent contrast from surrounding normal brain tissue on PET. Similar biodistributions between 68Ga-NOTA-Aca-BBN(7-14) and 68Ga-IRDye800CW-BBN PET were observed, while with additional uptake of brain blood pool on 68Ga-IRDye800CW-BBN PET at 30 and 60 min after tracer administration and lower uptake in normal brain tissues with the mean SUVs of 0.07 ± 0.03 (n=10) compared with 0.09 ± 0.04 (n=40) on 68Ga-NOTA-Aca-BBN(7-14) PET (P
-
Diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial
Wolters Kluwer Medknow Publications, 2017Co-Authors: Jie Zang, Hao Wang, Jing-jing Zhang, Zhaohui ZhuAbstract:Background: Gastrin-releasing peptide receptor is particularly expressed in gliomas, while the peptide bombesin [BBN(7-14)] has the complete C-terminal structure of human gastrin-releasing peptide. Glioma-specific imaging agents can therefore be constructed from BBN, for example 68Ga-NOTA-Aca-BBN(7-14). For consideration of the clinical translation of 68Ga-NOTA-Aca-BBN(7-14), an open-label dynamic whole-body positron emission tomography/computed tomography (PET/CT) study was designed to investigate the diagnostic effectiveness and safety of 68Ga-NOTA-Aca-BBN(7-14) in patients with brain gliomas. Methods/Design: This is an open-label single-arm clinical trial that will be conducted at Peking Union Medical College Hospital in Beijing, China. Thirty patients in suspicion of brain gliomas scheduled for surgical treatment will be recruited and subjected to PET/CT via intravenous injection of 68Ga-NOTA-Aca-BBN(7-14). The primary outcome measure will be the standardized uptake value of 68Ga-NOTA-Aca-BBN(7-14) in brain glioma at 30 minutes after injection. Secondary outcomes include the diagnostic accuracy rate of 68Ga-NOTA-Aca-BBN(7-14) PET/CT, and adverse events after injection. Discussion: Diagnostic performance and safety assessment of 68Ga-NOTA-Aca-BBN(7-14) in brain gliomas will provide new insights into the specific PET/CT diagnosis of brain gliomas. Trial registration: ClinicalTrials.gov identifier: NCT02520882, registered on 2 August 2015. Ethics: This study protocol has been approved by the Ethics Committee of Peking Union Medical College Hospital in China (approval No. S-714), and will be performed in accordance with the Declaration of Helsinki, formulated by the World Medical Association. Informed consent: An informed consent will be obtained from each patient or his/her guardian prior to participation in the study